Sanger sequencing is discussed as a “first-generation” technology that retains an important place in clinical genomics for orthogonal validation of NGS findings and for coverage of areas not amenable to NGS. With the number of NGS-based diagnostic tests and the laboratories providing them constantly growing, the issue of quality control and clinical oversight becomes highly important. Indeed, clinical sequencing provides test results to physicians, diagnoses are made